Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability

20 de marzo de 2017 actualizado por: Claus Behrend Christiansen, Nordsjaellands Hospital

The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability. A Randomised, Blinded, Healthy Volunteer Study

The aim is to investigate the effect of perineural administration of a series of different volumes of local anaesthesia (ropivacaine 0.2%) on nerve block duration and the variability of the duration in the common peroneal nerve and the sciatic nerve in healthy volunteers.

The hypothesis is that nerve block duration is correlated to local anaesthetic volume, but only to a certain degree. After a sufficient volume a 'saturation level' will be reached, and nerve block duration will not increase further.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

The trial is divided into two similar phases. Each phase will focus on a specific nerve. Phase 1 will focus on the common peroneal nerve and Phase 2 will focus on the sciatic nerve.

After baseline measurements, the investigators will insert a peripheral intravenous catheter. Then, the investigators will insert a suture-method peripheral nerve catheter (Certa CatheterTM). Procedures will be done in a sterile manner as a standard of practice. The investigators will use an ultrasound (US)-guided short-axis, needle in-plane technique. For the US-scan, the investigators will use a linear or a curvilinear transducer.

During interventions, volunteers will be monitored with continuous pulse oximetry. Placement of the peripheral nerve catheter will be facilitated by US using small injections of mepivacaine (carbocaine 2 %) in the skin and surrounding tissues and only isotonic saline (5 mL) in the perineural space to prevent blocking of the nerve before ropivacaine injection. The catheter orifice will be placed by pulling either end of the catheter and guided by the built-in echogenic markings seen on US. Before injection of ropivacaine, the investigators will do careful aspirations through the catheter in order to prevent intravasal injection.

Each ropivacaine injection will be administered via an infusion pump. This will ensure a constant infusion rate set to 10 mL per minute. During infusion, the volunteers will be monitored with continuous pulse oximetry.

Before instigation of the ropivacaine infusion, the investigators will use US to verify full absorption of the isotonic saline in the perineural space.

For each nerve, the subject will be randomly allocated to and receive one of five possible ropivacaine volumes. All volunteers and outcome assessors will be blinded to the ropivacaine administrations and infusion procedures. Outcome assessors will not be in the room, when the medication is prepared nor given. Preparation will take place behind a curtain and therefore also blinded to the volunteers.

Tipo de estudio

Intervencionista

Inscripción (Actual)

120

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Hillerød, Dinamarca, DK-3400
        • Claus Behrend Christiansen

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 64 años (Adulto)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria

  1. Male or female 18-64 years
  2. American Society of Anesthesiologists Classification ≤ II

Exclusion criteria

  1. Body Mass Index ≤ 18 or ≥ 30
  2. Former surgery to the lower extremities
  3. Peripheral nerve disease
  4. Allergy to ropivacaine
  5. Pregnancy or breastfeeding
  6. Enrolment in other investigational drug studies or recent clinical trials that may interfere with this study
  7. Habitual use of any kind of analgesic treatment
  8. Anatomic abnormalities preventing successful US-guided peripheral nerve catheter insertion

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Peroneal nerve: Ropivacaine 0.2%, 2.5 mL
Perineural injection of ropivacaine 0.2 %, 2,5 mL
Perineural injection.
Comparador activo: Peroneal nerve: Ropivacaine 0.2%, 5 mL
Perineural injection of ropivacaine 0.2 %, 5 mL
Perineural injection.
Comparador activo: Peroneal nerve: Ropivacaine 0.2%, 10 mL
Perineural injection of ropivacaine 0.2 %, 10 mL
Perineural injection.
Comparador activo: Peroneal nerve: Ropivacaine 0.2%, 15 mL
Perineural injection of ropivacaine 0.2 %, 15 mL
Perineural injection.
Comparador activo: Peroneal nerve: Ropivacaine 0.2%, 20 mL
Perineural injection of ropivacaine 0.2 %, 20 mL
Perineural injection.
Comparador activo: Sciatic nerve: Ropivacaine 0.2%, 5 mL
Perineural injection of ropivacaine 0.2 %, 5 mL
Perineural injection.
Comparador activo: Sciatic nerve: Ropivacaine 0.2%, 10 mL
Perineural injection of ropivacaine 0.2 %, 10 mL
Perineural injection.
Comparador activo: Sciatic nerve: Ropivacaine 0.2%, 15 mL
Perineural injection of ropivacaine 0.2 %, 15 mL
Perineural injection.
Comparador activo: Sciatic nerve: Ropivacaine 0.2%, 20 mL
Perineural injection of ropivacaine 0.2 %, 20 mL
Perineural injection.
Comparador activo: Sciatic nerve: Ropivacaine 0.2%, 30 mL
Perineural injection of ropivacaine 0.2 %, 30 mL
Perineural injection.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Duration of sensory nerve block
Periodo de tiempo: 1-24 hours
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start after onset of sensory nerve block and continue until normal sensation has returned. When testing the sciatic nerve, we will continue testing until normal sensation has returned in both components of the nerve, i.e. the tibial and common peroneal nerve.
1-24 hours

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Length of nerve exposed to local anaesthesia
Periodo de tiempo: 10 minutes
We will measure local anaesthetic spread in a proximal-to-distal manner parallel to the nerve trajectory. Total length of the neural spread will be reported in millimetres from the most proximal point to the most distal point in which fluid, i.e. ropivacaine, is seen on ultrasound in proximity to the nerve. Testing will be done immediately after end of ropivacaine infusion.
10 minutes
Onset of sensory nerve block
Periodo de tiempo: 10-180 minutes
Application of a round, cooled glass container in the sensory distribution area of the tested nerve: The lateral part of the lower leg for the common peroneal nerve and beneath the foot for the tibial nerve. Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. We will test for a maximum of 180 minutes.
10-180 minutes
Onset of motor nerve block
Periodo de tiempo: 10-180 minutes
Testing will start ten minutes after end of infusion and continue for every fifth minute until onset. When onset of sensory nerve block is confirmed, testing of motor nerve block onset will end as well, if not already found. Motor nerve block of the tibial nerve will be evaluated by plantarflexion of the ankle. Motor nerve block of the common peroneal nerve will be tested by dorsiflexion of the ankle.
10-180 minutes
Degree of sensory nerve block
Periodo de tiempo: 1-24 hours
We will test sensory nerve block using a subjective rating scale. We will grade from one to four: 1) "not different from ipsilateral antebrachium"; 2) "different from ipsilateral antebrachium"; 3) "warm sensation"; 4) "no sensation". Grades 2-4 will be considered as successful sensory nerve blocks. It will be noted if the volunteer is in doubt. Nevertheless, this will be considered as a successful sensory nerve block and graded as 2) in the post hoc statistical analyses.
1-24 hours
Degree of motor nerve block
Periodo de tiempo: 1-24 hours
This will be tested with the volunteer in the upright position using a sturdy counter for balance if necessary. Motor strength will be evaluated using a normal everyday activation of the lower leg: A toe and a heel raise, testing the common peroneal nerve via activation of the anterior tibial muscle and the tibial nerve via activation of the gastrocnemius muscle, respectively. Motor nerve block intensity will be evaluated on a scale from one to three: 1) normal strength, 2) paresis or 3) paralysis. Volunteers will be asked to perform a maximum contraction building up muscle force over three seconds. It will be noted if the volunteer is in doubt, which will be considered as 2) paresis in the post hoc statistical analyses.
1-24 hours

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Director de estudio: Kai Henrik Wiborg Lange, MD DMSC, Nordsjællands Hospital Hillerød

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de julio de 2016

Finalización primaria (Actual)

20 de marzo de 2017

Finalización del estudio (Actual)

20 de marzo de 2017

Fechas de registro del estudio

Enviado por primera vez

8 de julio de 2016

Primero enviado que cumplió con los criterios de control de calidad

8 de julio de 2016

Publicado por primera vez (Estimar)

12 de julio de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de marzo de 2017

Última actualización enviada que cumplió con los criterios de control de calidad

20 de marzo de 2017

Última verificación

1 de marzo de 2017

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Descripción del plan IPD

We will attach relevant data sheets to all our scientific submissions.

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir